Edition:
India

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

23.52USD
23 Jan 2018
Change (% chg)

$0.85 (+3.75%)
Prev Close
$22.67
Open
$22.58
Day's High
$23.64
Day's Low
$22.51
Volume
74,964
Avg. Vol
76,298
52-wk High
$28.62
52-wk Low
$18.67

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $1,163.30
Shares Outstanding(Mil.): 46.93
Dividend: --
Yield (%): --

Financials

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

05 Jan 2018

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

05 Dec 2017

BRIEF-Xencor posts Q3 loss of $0.33 per share

* Xencor reports third quarter 2017 financial results and provides clinical pipeline update

08 Nov 2017

BRIEF-Xencor Q2 loss per share $0.15

* Qtrly earnings per share $0.15 Source text for Eikon: Further company coverage:

08 Aug 2017

Competitors

Earnings vs. Estimates